Watch for enrollment updates and interim data readouts from the NEPTUNE trial, as positive results could be transformative for this early-stage biotech. The registrational design means any efficacy signal will directly impact approval probability.
Price Chart
Executive Summary
OKYO Pharma announced first patients enrolled in the Phase 3 NEPTUNE trial of urcosimod for neuropathic corneal pain (NCP), a condition with no FDA-approved treatments. This is a key milestone for the registrational study, which is designed to support a potential first-in-class therapy for a significant unmet medical need.
Key Facts
- First patients enrolled in Phase 3 NEPTUNE trial of urcosimod for neuropathic corneal pain (NCP).
- Trial is a registrational study per FDA guidance, with primary endpoint of change in ocular pain (VAS score) at 12 weeks.
- No FDA-approved treatments currently exist for NCP, representing a significant unmet medical need.
- Enrollment expanding across multiple U.S. and European sites (Italy, Spain, France).
- Urcosimod is a first-in-class lipid-conjugated chemerin peptide agonist with dual analgesic and anti-inflammatory mechanism.
Financial Impact
No financial figures disclosed; trial initiation milestone with no revenue or cost data provided.
Risk Factors
- Phase 3 trial failure risk — no prior efficacy data in NCP from a controlled study.
- Early-stage biotech with no approved products or revenue; financing risk for trial completion.
- Competing therapies in development for NCP could emerge.
Investment Themes
Documents Analyzed
This report is based on 1 press release from GlobeNewswire.
| Document | Accession Number |
|---|---|
| PRESS-RELEASE Data (Synthetic) | press-3375318 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Oct 6, 2026 21d ago | 6-K | $1.46 $1.41 | ▼ −3.42% | ▼ −3.18% | $1.44 (−1.37%) |
Oct 6, 2026 21d ago | Press Release | $1.46 $1.41 | ▼ −3.42% | ▼ −3.18% | $1.44 (−1.37%) |
Sep 29, 2026 28d ago | 6-K | $1.36 $1.29 | ▼ −5.15% | ▼ −4.94% | $1.44 (+5.88%) |
Sep 8, 2026 7w ago | 6-K | $1.53 $1.45 | ▼ −5.23% | ▼ −4.76% | $1.44 (−5.88%) |
Aug 7, 2026 11w ago | Insider Cluster | $1.57 $1.52 | ▼ −3.18% | ▼ −2.87% | $1.44 (−8.28%) |
Jul 28, 2026 13w ago | 6-K | $1.64 $1.64 | · 0.00% | ▲ +1.54% | $1.44 (−12.20%) |
Jul 27, 2026 13w ago | 6-K | $1.64 $1.64 | · 0.00% | ▼ −0.24% | $1.44 (−12.20%) |
Jul 23, 2026 13w ago | 6-K | $1.48 $1.55 | ▲ +4.73% | ▲ +4.63% | $1.44 (−2.70%) |
Jul 23, 2026 13w ago | Press Release | $1.48 $1.55 | ▲ +4.73% | ▲ +4.63% | $1.44 (−2.70%) |
Jul 23, 2026 13w ago | 6-K | $1.48 $1.55 | ▲ +4.73% | ▲ +4.63% | $1.44 (−2.70%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers